VEGFA and cancer: For patients with HER2-negative G/GEJ cancers, there have been multiple failures in the first-line setting to improve survival with the addition of a new agent to chemotherapy based regimens, including: the anti-epidermal growth factor receptor antibodies cetuximab [6] and panitumumab [7]; vascular endothelial growth factor (VEGF) pathway targeting antibodies ramucirumab [8,9] and bevacizumab [10]; antibodies targeting the MET receptor ligand rilotumumab [11] and onartuzumab [12]; and the antibody targeting matrix metalloproteinase-9 andecaliximab [13].